These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4. Lennon D Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051 [No Abstract] [Full Text] [Related]
4. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089 [TBL] [Abstract][Full Text] [Related]
5. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351 [TBL] [Abstract][Full Text] [Related]
6. Group B meningococcal vaccine science and policy. Drysdale SB; Pollard AJ J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798 [TBL] [Abstract][Full Text] [Related]
7. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Martin NG; Snape MD Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957 [TBL] [Abstract][Full Text] [Related]
8. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9. Lennon D Vaccine; 2007 Sep; 25(39-40):6835; author reply 6835-6. PubMed ID: 17875437 [No Abstract] [Full Text] [Related]
9. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369 [TBL] [Abstract][Full Text] [Related]
10. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine. Brendish NJ; Read RC Expert Rev Vaccines; 2015 Apr; 14(4):493-503. PubMed ID: 25703792 [TBL] [Abstract][Full Text] [Related]
11. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053 [TBL] [Abstract][Full Text] [Related]
12. Development of a vaccine against serogroup B has been the main scientific challenge. Preface. Rappuoli R; Pizza M; Black S; Moxon ER Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893 [No Abstract] [Full Text] [Related]
13. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467 [TBL] [Abstract][Full Text] [Related]
14. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Su EL; Snape MD Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979 [TBL] [Abstract][Full Text] [Related]
15. Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease. Anderson AS; Hao L; Jiang Q; Harris SL; Jones TR; Perez JL; York L; Eiden J; Jansen KU Hum Vaccin Immunother; 2013 Mar; 9(3):471-9. PubMed ID: 23249817 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223 [TBL] [Abstract][Full Text] [Related]
17. The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential. Hung MC; Heckels JE; Christodoulides M mBio; 2013 Feb; 4(2):. PubMed ID: 23443003 [TBL] [Abstract][Full Text] [Related]
18. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine. Esposito S; Principi N Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061 [TBL] [Abstract][Full Text] [Related]
19. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400 [TBL] [Abstract][Full Text] [Related]
20. Meningococcal B vaccine development and evaluation of efficacy. van Alphen L; van den Dobbelsteen G Hum Vaccin; 2008; 4(2):158-61. PubMed ID: 18388494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]